Search Results - "Raynor, Jackson F."

Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma by Burrack, Adam L., Spartz, Ellen J., Raynor, Jackson F., Wang, Iris, Olson, Margaret, Stromnes, Ingunn M.

“…Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer resistant to immunotherapy. We create a PDA mouse model and show that neoantigen expression is…”
Get full text

Germline T cell receptor exchange results in physiological T cell development and function by Rollins, Meagan R., Raynor, Jackson F., Miller, Ebony A., Butler, Jonah Z., Spartz, Ellen J., Lahr, Walker S., You, Yun, Burrack, Adam L., Moriarity, Branden S., Webber, Beau R., Stromnes, Ingunn M.

“…T cell receptor (TCR) transgenic mice represent an invaluable tool to study antigen-specific immune responses. In the pre-existing models, a monoclonal TCR is…”
Get full text

Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer by Burrack, Adam L, Schmiechen, Zoe C, Patterson, Michael T, Miller, Ebony A, Spartz, Ellen J, Rollins, Meagan R, Raynor, Jackson F, Mitchell, Jason S, Kaisho, Tsuneyasu, Fife, Brian T, Stromnes, Ingunn M

“…We investigate how myeloid subsets differentially shape immunity to pancreatic ductal adenocarcinoma (PDA). We show that tumor antigenicity sculpts myeloid…”
Get full text

CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model by Burrack, Adam L, Rollins, Meagan R, Spartz, Ellen J, Mesojednik, Taylor D, Schmiechen, Zoe C, Raynor, Jackson F, Wang, Iris X, Kedl, Ross M, Stromnes, Ingunn M

“…Pancreatic cancer is a particularly lethal malignancy that resists immunotherapy. In this study, using a preclinical pancreatic cancer murine model, we…”
Get full text

Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma by Stromnes, Ingunn M, Burrack, Adam L, Hulbert, Ayaka, Bonson, Patrick, Black, Cheryl, Brockenbrough, J Scott, Raynor, Jackson F, Spartz, Ellen J, Pierce, Robert H, Greenberg, Philip D, Hingorani, Sunil R

“…Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy resistant to therapies, including immune-checkpoint blockade. We investigated two distinct…”
Get more information

Agonistic anti-CD40 overcomes T cell exhaustion induced by chronic myeloid cell IL-27 production in a pancreatic cancer preclinical model by Burrack, Adam L., Rollins, Meagan R., Spartz, Ellen J., Mesojednik, Taylor D., Schmiechen, Zoe C., Raynor, Jackson F., Wang, Iris, Kedl, Ross M., Stromnes, Ingunn M.

“…Pancreatic cancer is a particularly lethal malignancy and resists immunotherapy. Here, using a preclinical pancreatic cancer murine model, we demonstrate a…”
Get full text

Abstract NG12: Mechanisms governing efficacy of combination CD40 agonist and anti-PD-L1 in pancreatic ductal adenocarcinoma by Burrack, Adam L., Rollins, Meagan R., Spartz, Ellen J., Raynor, Jackson F., Wang, Iris, Mitchell, Jason, Kaisho, Tsuneyasu, Fife, Brian, Kedl, Ross, Shen, Stephen, Stromnes, Ingunn M.

“…Abstract Background: Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy that is resistant to conventional therapies including monotherapy using PD-1…”
Get full text